Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our results suggest that high homocysteine levels are a further risk factor for TTR cardiomyopathy in patients harbouring the L55P-TTR mutation.
|
31676294 |
2020 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense oligonucleotide therapy, inotersen, in transthyretin cardiomyopathy.<b>Methods:</b> Patients with hereditary or wildtype transthyretin cardiomyopathy (NYHA I-III) with an LV wall thickness [Formula: see text]1.3 cm and clinical evidence of congestive heart failure were eligible for this single centre, open label protocol.
|
31713445 |
2020 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our findings reveal that ATTR p.A97S is a cardiomyopathy as well as a polyneuropathic syndrome.
|
31521469 |
2020 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
<b>Background:</b> Patients with transthyretin (TTR) cardiac amyloidosis demonstrate cardiac cachexia with progression of their cardiomyopathy, which is characterised by malnutrition and a heightened inflammatory state.
|
31825676 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Conclusion:</b> Tafamidis is an effective and safe oral medication for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
|
31735059 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
The drug resulted safe also in long term follow-up studies while its efficacy for ATTR with cardiomyopathy is under investigation.
|
31566422 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
|
30885685 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized progressive cardiomyopathy with heterogenous clinical manifestations that lead to its misdiagnosis and poor prognosis.
|
31718691 |
2019 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Late-onset and fast progressive neuropathy and cardiomyopathy in Val32Ala transthyretin gene mutation.
|
30685801 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an underappreciated cause of heart failure that results from misfolded TTR (prealbumin) protein.
|
31805416 |
2019 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The altered structure of TTR due to genetic mutations or its deposits due to aggregation could cause several deadly diseases such as cardiomyopathy and neuropathy in autonomic, motor, and sensory systems.
|
31216785 |
2019 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel<sup>®</sup>, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses.
|
31735731 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
There have now been randomized controlled trials of four different therapeutics for hereditary amyloid polyneuropathy related to transthyretin (TTR) deposition and one for amyloidotic cardiomyopathy of both genetic and sporadic origin.
|
30907141 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
As previously seen for ATTR amyloidosis patients with mainly cardiomyopathy, the amyloid fibrils consisted of a mixture of full-length and fragmented TTR species.
|
31169435 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
TTR-related amyloidosis (ATTR) is manifested in two allelic forms: familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-FAC), both caused by mutations in the TTR gene.
|
30981840 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.
|
31118583 |
2019 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Included in this review is an overview of red flag signs and symptoms and a recommended diagnostic approach, including testing for monoclonal protein, scintigraphy, or biopsy and, if ATTR associated with cardiomyopathy is identified, TTR genotyping.
|
31480867 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
ATTR-CM is an inexorably progressive and eventually fatal cardiomyopathy associated with poor quality of life.
|
31109193 |
2019 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Inotersen: First Global Approval.
|
30120737 |
2018 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Transthyretin (ATTR) amyloidosis is an under-recognized, progressive disease manifesting as cardiomyopathy and/or polyneuropathy.
|
30388377 |
2018 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Cardiac transthyretin-related amyloidosis (ATTR) is a progressive and fatal cardiomyopathy.
|
29687207 |
2018 |
Cardiomyopathies
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?
|
30374850 |
2018 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Tafamidis is a TTR stabilizer that is orally administered and, by interfering with amyloid fibril formation and deposition, is capable of slowing progression of TTR polyneuropathy and of early-stage cardiomyopathy.
|
29779881 |
2018 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Aggregation of transthyretin (TTR) is the causative agent for TTR cardiomyopathy and polyneuropathy amyloidoses.
|
29915031 |
2018 |
Cardiomyopathies
|
0.500 |
Biomarker
|
group |
BEFREE |
Transthyretin (TTR)-related cardiac amyloidosis is a progressive infiltrative cardiomyopathy that mimics hypertensive, hypertrophic heart disease and may go undiagnosed.
|
28840452 |
2017 |